OncRef

Clinical Trial: NCT04294810

A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

Status:

COMPLETED

Phase:

Phase 3

Lead Sponsor:Hoffmann-La Roche
Information Provided By:Hoffmann-La Roche
Last Update Posted:2026-01-30

Study Overview

Brief Summary

The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally advanced, unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. Eligible participants will be randomized in a 1:1 ratio to receive either tiragolumab plus atezolizumab or placebo plus atezolizumab.

Official Title

A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

Conditions

Non-Small Cell Lung Cancer

Intervention / Treatment

  • Drug: Atezolizumab
  • Drug: Tiragolumab
  • Drug: Matching Placebo

Other Study ID Numbers

  • GO41717
  • 2019-002925-31
  • 2022-502482-17-00
  • 2019

Start Date (Actual)

2020-03-04

Primary Completion Date (Actual)

2025-12-30

Study Completion Date (Actual)

2025-12-30

Enrollment (Actual)

620

Study Type

Interventional

Phase

Phase 3